These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 380227)

  • 1. [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
    Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
    Z Urol Nephrol; 1979 Mar; 72(3):153-7. PubMed ID: 380227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
    Guddat HM; Schnorr D; Dörner G; Stahl F; Rhode W
    Z Urol Nephrol; 1987 Mar; 80(3):125-33. PubMed ID: 3604471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
    Böhm WD; Gorski J; Geissler W; Illig HD; Koch R
    Z Urol Nephrol; 1987 Mar; 80(3):159-64. PubMed ID: 2440199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conservative therapy of prostate cancer using Turisteron].
    Schnorr D; Dörner G; Stahl F; Rohde W; Guddat HM
    Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secondary endocrine therapy with oral estrogen for relapsed prostate cancer].
    Onita T; Igawa T; Hisamatsu H; Sakai H; Kanetake H
    Hinyokika Kiyo; 2009 Oct; 55(10):595-8. PubMed ID: 19926941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
    Gorski J; Böhm WD; Illig HD; Koch R
    Urologe A; 1988 Sep; 27(5):287-90. PubMed ID: 3051628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.
    Stahl F; Schnorr D; Bär CM; Fröhlich G; Dörner G
    Exp Clin Endocrinol; 1989; 94(3):239-43. PubMed ID: 2630306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
    Stahl F; Schnorr D; Rohde W; Dörner G
    Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
    Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
    Z Urol Nephrol; 1987 Dec; 80(12):665-8. PubMed ID: 3126615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy in carcinoma of the prostate].
    Marberger H
    Wien Klin Wochenschr; 1966 Jul; 78(29):512-4 passim. PubMed ID: 5992834
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron).
    Dörner G; Schnorr D; Stahl F; Rohde W
    Exp Clin Endocrinol; 1985 Dec; 86(2):190-6. PubMed ID: 3912197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of 3H-5 -dihydrotestosterone metabolism in normal men and women and men with prostatic carcinoma; effects of estrogen administration in men.
    Bird CE; Clark AF
    J Clin Endocrinol Metab; 1972 Mar; 34(3):467-72. PubMed ID: 5011250
    [No Abstract]   [Full Text] [Related]  

  • 14. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
    Guddat HM; Schnorr D; Zemke F
    Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
    Kaplan L
    Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Orchidectomy and oestrogen therapy of carcinoma of the prostate (author's transl)].
    Straube W; Braun JS
    Urologe A; 1974 Jul; 13(4 Pt A):198-201. PubMed ID: 4137442
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal therapy of prostatic carcinoma].
    Martz G
    Internist (Berl); 1968 Sep; 9(9):375-80. PubMed ID: 4918657
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
    Wallentin L; Varenhorst E
    J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.